These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 38610954)

  • 21. Immunotherapy: a promising approach for glioma treatment.
    Yasinjan F; Xing Y; Geng H; Guo R; Yang L; Liu Z; Wang H
    Front Immunol; 2023; 14():1255611. PubMed ID: 37744349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
    Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
    J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.
    Sener U; Ruff MW; Campian JL
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations.
    Niedbała M; Malarz K; Sharma G; Kramer-Marek G; Kaspera W
    Onco Targets Ther; 2022; 15():437-468. PubMed ID: 35509452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
    Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
    Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
    [No Abstract]   [Full Text] [Related]  

  • 26. Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma.
    Webb MJ; Sener U; Vile RG
    Pharmaceuticals (Basel); 2023 May; 16(6):. PubMed ID: 37375742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
    Tang L; Zhang M; Liu C
    Front Immunol; 2022; 13():882257. PubMed ID: 35651605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged.
    Van Gool SW; Makalowski J; Fiore S; Sprenger T; Prix L; Schirrmacher V; Stuecker W
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Immunotherapeutic Approaches for Glioblastoma.
    Vázquez Cervantes GI; González Esquivel DF; Gómez-Manzo S; Pineda B; Pérez de la Cruz V
    J Immunol Res; 2021; 2021():3412906. PubMed ID: 34557553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
    Majd N; de Groot J
    Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
    [No Abstract]   [Full Text] [Related]  

  • 34. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy.
    Fekrirad Z; Barzegar Behrooz A; Ghaemi S; Khosrojerdi A; Zarepour A; Zarrabi A; Arefian E; Ghavami S
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Innate Immunity in Glioma Therapy.
    Gillard AG; Shin DH; Hampton LA; Lopez-Rivas A; Parthasarathy A; Fueyo J; Gomez-Manzano C
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022.
    Gatto L; Franceschi E; Tosoni A; Di Nunno V; Bartolini S; Brandes AA
    Expert Opin Drug Discov; 2023 Mar; 18(3):269-286. PubMed ID: 36718723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging Trends in Immunotherapy for Cancer.
    Mishra AK; Ali A; Dutta S; Banday S; Malonia SK
    Diseases; 2022 Sep; 10(3):. PubMed ID: 36135216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.